Curis Inc surges 28% amid market context
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 07 Jan 26
Source: Coinmarketcap
Curis Inc's stock price has surged by 28.00% in pre-market trading, as it crosses above the 20-day SMA. This movement occurs in a mixed market environment, with the Nasdaq-100 down 0.07% while the S&P 500 is up 0.07%.
The surge is attributed to sector rotation, as investors are shifting their focus towards biotech stocks despite the slight decline in the Nasdaq-100. This indicates a potential shift in investor sentiment towards companies like Curis Inc, which may benefit from increased interest in the biotech sector.
This price movement suggests that Curis Inc is gaining traction among investors, potentially positioning itself for further growth as market dynamics evolve.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11.00 USD with a low forecast of 5.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.916
Low
5.00
Averages
11.00
High
17.00
Current: 0.916
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
